Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$554M |
| 2 |
Apple
AAPL
|
+$513M |
| 3 |
Illumina
ILMN
|
+$360M |
| 4 |
argenx
ARGX
|
+$304M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$482M |
| 2 |
Sherwin-Williams
SHW
|
+$314M |
| 3 |
AbbVie
ABBV
|
+$310M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$244M |
| 5 |
Atlassian
TEAM
|
+$233M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.47% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CANO
2651
DELISTED
Cano Health, Inc.
CANO
| $56.6K | ﹤0.01% |
621
+391
| +170% | +$53.1K |
|
|
AEVA
2652
Aeva Technologies
AEVA
$1.71B
| $55.1K | ﹤0.01% |
9,260
+4,828
| +109% | +$38.7K |
|
2653
Fulcrum Therapeutics
FULC
$280M
| $54K | ﹤0.01% |
+18,972
| New | +$170K |
|
|
NGM
2654
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $53K | ﹤0.01% |
+13,007
| New | +$60.1K |
|
2655
Evolv Technologies
EVLV
$1.08B
| $52K | ﹤0.01% |
+16,699
| New | +$47.7K |
|
2656
Smartbird Inc
BIRD
$22.2M
| $49.7K | ﹤0.01% |
2,079
+1,072
| +106% | +$49.4K |
|
2657
Traeger
COOK
$175M
| $49.6K | ﹤0.01% |
+242
| New | +$43.3K |
|
|
NXDR
2658
Nextdoor Holdings
NXDR
$1.03B
| $49.3K | ﹤0.01% |
+22,961
| New | +$49K |
|
|
MMAT
2659
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $49.2K | ﹤0.01% |
1,204
+814
| +209% | +$63.2K |
|
2660
Advantage Solutions
ADV
$376M
| $48.9K | ﹤0.01% |
1,231
+730
| +146% | +$41.2K |
|
2661
Latham Group
SWIM
$869M
| $48.2K | ﹤0.01% |
+16,919
| New | +$59.4K |
|
|
ESPR
2662
DELISTED
Esperion Therapeutics
ESPR
| $47.5K | ﹤0.01% |
29,767
+13,669
| +85% | +$70.6K |
|
2663
Tango Therapeutics
TNGX
$4.32B
| $47.4K | ﹤0.01% |
+11,986
| New | +$69.6K |
|
2664
Precigen
PGEN
$2.46B
| $46.6K | ﹤0.01% |
44,183
+26,235
| +146% | +$37.8K |
|
|
GOEV
2665
DELISTED
Canoo Inc. Class A Common Stock
GOEV
| $43.5K | ﹤0.01% |
146
+98
| +204% | +$41.5K |
|
2666
Organogenesis Holdings
ORGO
$235M
| $41.9K | ﹤0.01% |
19,706
-79,398
| -80% | -$196K |
|
2667
Rackspace Technology
RXT
$1.16B
| $41.3K | ﹤0.01% |
+22,015
| New | +$56.6K |
|
2668
Holley
HLLY
$387M
| $35.5K | ﹤0.01% |
+12,988
| New | +$33.2K |
|
2669
C4 Therapeutics
CCCC
$419M
| $34.7K | ﹤0.01% |
11,081
-727,548
| -98% | -$4.28M |
|
2670
Outdoor Holding Co
POWW
$283M
| $32.9K | ﹤0.01% |
16,698
-28,303
| -63% | -$58.5K |
|
2671
Veru
VERU
$43.8M
| $31.9K | ﹤0.01% |
2,758
+1,483
| +116% | +$60K |
|
|
CRGE
2672
DELISTED
Charge Enterprises, Inc. Common Stock
CRGE
| $30.5K | ﹤0.01% |
+27,816
| New | +$35K |
|
|
TSP
2673
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
| $29.2K | ﹤0.01% |
+19,767
| New | +$37.4K |
|
|
GTHX
2674
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $28.3K | ﹤0.01% |
+10,566
| New | +$50.8K |
|
|
HYZN
2675
DELISTED
Hyzon Motors Inc. Class A Common Stock
HYZN
| $27K | ﹤0.01% |
662
+334
| +102% | +$24.9K |
|
Similar funds
Janus Henderson Group's Q1 2023 Portfolio in Review
As of Q1 2023, Janus Henderson Group held 2,845 positions worth $152B, up 8.3% from $140B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Janus Henderson Group's Q1 2023 filing shows 389 new, 1,670 increased, 578 reduced and 160 closed positions. Its largest new stake was GE HealthCare: 882,749 shares worth $72.4M. The largest sale was Meta Platforms (Facebook), an estimated $482M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 28% a quarter earlier, followed by Healthcare and Industrials.
- Janus Henderson Group's largest Q1 2023 buy was GE HealthCare: 882,749 shares worth $72.4M.
- Janus Henderson Group added most to Linde in Q1 2023, an estimated $554M increase.
- Janus Henderson Group's biggest Q1 2023 reduction was Meta Platforms (Facebook), cutting an estimated $482M.
- Janus Henderson Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $31.7M.
- Janus Henderson Group's ten largest holdings make up 24% of its $152B portfolio in Q1 2023.
- Janus Henderson Group opened 389 new positions and closed 160 in Q1 2023.
- Janus Henderson Group's portfolio value rose 8.3% quarter-over-quarter to $152B.
Based on Janus Henderson Group's 13F filing for Q1 2023, filed 15 May 2023.